CIK 0000744218 · Large accelerated filer
Celldex Therapeutics, Inc.
Sign in to watch- Ticker
- CLDX
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 133191702
- Phone
- 908-200-7500
- Business address
- 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827
- Former names
- AVANT IMMUNOTHERAPEUTICS INC, T CELL SCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-15 | KELER TIBOR EXECUTIVE VP & CSO | Grant or award · Incentive Stock Option (right to buy) | +92,000 | 92,000 | ||
| 2023-06-15 | Marucci Anthony S PRESIDENT & CEO | Grant or award · Incentive Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2023-06-15 | Brownlie Keith L Director | Grant or award · Non-Qualified Stock Option (right to buy) | +11,300 | 11,300 | ||
| 2023-06-15 | PENNER HARRY JR Director | Grant or award · Non-Qualified Stock Option (right to buy) | +11,300 | 11,300 | ||
| 2023-06-15 | NEIL GARRY ARTHUR Director | Grant or award · Non-Qualified Stock Option (right to buy) | +11,300 | 11,300 | ||
| 2023-06-15 | MARINO JAMES J Director | Grant or award · Non-Qualified Stock Option (right to buy) | +11,300 | 11,300 | ||
| 2023-06-15 | CONRAD HERBERT J Director | Grant or award · Non-Qualified Stock Option (right to buy) | +11,300 | 11,300 | ||
| 2023-06-15 | Cohen Cheryl Director | Grant or award · Non-Qualified Stock Option (right to buy) | +11,300 | 11,300 | ||
| 2023-06-15 | Shoos Karen L. Director | Grant or award · Non-Qualified Stock Option (right to buy) | +11,300 | 11,300 | ||
| 2023-02-16 | Jain Rita Director | Grant or award · Non-Qualified Stock Option (right to buy) | +17,100 | 17,100 | ||
| 2022-12-07 | KELER TIBOR EXECUTIVE VP & CSO | Option exercise | +16,860 | $2.78 | $47K | 24,217 |
| 2022-12-07 | KELER TIBOR EXECUTIVE VP & CSO | Sale | −16,860 | $36.93 | $623K | 7,357 |
| 2022-12-07 | KELER TIBOR EXECUTIVE VP & CSO | Option exercise · Incentive Stock Option (right to buy) | −16,860 | 43,140 | ||
| 2022-08-18 | Cavanaugh Sarah SVP OF CORP AFFAIRS & ADMIN. | Option exercise | +1,355 | $9.02 | $12K | 2,639 |
| 2022-08-18 | Cavanaugh Sarah SVP OF CORP AFFAIRS & ADMIN. | Sale | −1,355 | $36.38 | $49K | 1,284 |
| 2022-08-18 | Cavanaugh Sarah SVP OF CORP AFFAIRS & ADMIN. | Option exercise · Incentive Stock Option | −1,355 | 10,103 | ||
| 2022-08-17 | Cavanaugh Sarah SVP OF CORP AFFAIRS & ADMIN. | Option exercise | +31,312 | $2.78 | $87K | 32,596 |
| 2022-08-17 | Cavanaugh Sarah SVP OF CORP AFFAIRS & ADMIN. | Sale | −31,312 | $36.73 | $1.2M | 1,284 |
| 2022-08-17 | Cavanaugh Sarah SVP OF CORP AFFAIRS & ADMIN. | Option exercise · Incentive Stock Option | −31,312 | 10,750 | ||
| 2022-08-17 | Young Diane C. SVP, CHIEF MEDICAL OFFICER | Option exercise | +19,000 | $10.38 | $197K | 21,115 |
Page 8 of 10 · 182 trades